Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence

Pharmacotherapies Research Unit, Drug and Alcohol Services South Australia, South Australia, Australia.
Addiction (Impact Factor: 4.74). 10/2009; 105(1):146-54. DOI: 10.1111/j.1360-0443.2009.02717.x
Source: PubMed


To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexamphetamine in people dependent on methamphetamine.
Randomized, double-blind, placebo-controlled trial.
Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia (DASSA) clinics.
Participants were assigned randomly to receive up to 110 mg/day sustained-release dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks. Medication was taken daily under pharmacist supervision.
Primary outcome measures included treatment retention, measures of methamphetamine consumption (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry.
Treatment retention was significantly different between groups, with those who received dexamphetamine remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014). There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086). Based on hair analysis, there was a significant decrease in methamphetamine concentration for both groups (P < 0.0001). At follow-up, degree of methamphetamine dependence was significantly lower in the dexamphetamine group (P = 0.042). Dexamphetamine maintenance was not associated with serious adverse events.
The results of this preliminary study have demonstrated that a maintenance pharmacotherapy programme of daily sustained-release amphetamine dispensing under pharmacist supervision is both feasible and safe. The increased retention in the dexamphetamine group, together with the general decreases in methamphetamine use, degree of dependence and withdrawal symptom severity, provide preliminary evidence that this may be an efficacious treatment option for methamphetamine dependence.

Download full-text


Available from: Matthew Smout, Jul 04, 2014
  • Source
    • "The general class of abused stimulants also includes drugs such as amphetamine , methamphetamine, and emerging cathinone analogs that function as substrates at dopamine transporters to promote dopamine release (Baumann et al, 2012a; Cameron et al, 2013; Rothman et al, 2001). Recent clinical trials and a human laboratory study found that amphetamine maintenance failed to produce significant decreases in methamphetamine consumption (Galloway et al, 2011; Longo et al, 2010; Pike et al, 2014). These and related results have been interpreted to suggest that dopamine releasers such as amphetamine may be more effective to treat abuse of dopamine uptake inhibitors (eg, cocaine) than abuse of other dopamine releasers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology, publishing the highest quality original research and advancing our understanding of the brain and behavior.
    Full-text · Article · Dec 2014 · Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology
  • Source
    • "August 2012 | Volume 3 | Article 77 | 1 Longo et al. (2010) reported d-amphetamine produced enhanced retention and decreased illicit use in a methamphetamine abusing population. These reports, along with multiple community clinic and case series reports of reductions in amphetamine abuse during d-amphetamine maintenance, point to potential utility. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction. We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo. Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200 mg plus d-amphetamine 30 mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication. Results: Retention rates did not differ between groups and were generally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups. The study medications were generally well-tolerated with few adverse effects, yet rates of adherence were suboptimal (≤80%). Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.
    Full-text · Article · Aug 2012 · Frontiers in Psychiatry
  • Source
    • "Interestingly, this trial was halted early due to significant clinical decline in a comparison group treated with aripiprazole. Finally, a recent randomized, controlled trial conducted in methamphetamine dependent subjects (n=80) found significantly improved retention, lower level of dependence, and a trend toward greater reduction in methamphetamine use in subjects treated with dexamphetamine as compared to those receiving placebo (Longo et al., 2009). Unfortunately, none of these studies systematically evaluated the effects of stimulant treatment on cognitive functioning or ability to engage in cognitive behavioral therapy, so the role of improvement in cognitive function in any positive studies in unclear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Attenuation of drug reward has been the major focus of medication development in the addiction area to date. With the growth of research in the area of cognitive neuroscience, the importance of executive function and inhibitory cognitive control in addictive disorders is becoming increasingly apparent. An emerging strategy in the pharmacotherapy of addictions and other psychiatric disorders involves the use of medications that improve cognitive function. In particular, agents that facilitate inhibitory and attentional control, improve abstraction, planning and mental flexibility could be beneficial in the treatment of substance use disorders. Because there are multiple neurotransmitter systems involved in the regulation of cognitive function, agents from a number of drug classes have been tested. In particular, agents acting through the cholinergic, adrenergic and glutamatergic systems have shown potential for improving cognitive function in a number of psychiatric and neurologic disorders, but most of these agents have not been tested in the treatment of individuals with substance use disorders. This manuscript provides a review of clinical data supporting the use of the major classes of cognitive enhancing agents in substance use disorders. Agents that have shown promise in cognitive enhancement in other disorders, and have a theoretical or mechanistic rationale for application to substance use disorders are also highlighted.
    Full-text · Article · Aug 2011 · Pharmacology Biochemistry and Behavior
Show more